Acrivon Therapeutics

Acrivon Therapeutics specializes in accelerated drug development in oncology, using a unique, predictive phospho-proteomic approach. Their patented technology platform identifies drug-tailored biomarker signatures for patient responder identification, which increases efficacy, reduces toxicity and precisely matches the therapy with patients who will benefit.